ARCHIVES

Bypass Budget Is Realistic, Defensible Plan, Broder Says

This article is from The Cancer Letter archive.

Vol. 17 No. 37 | September 27, 1991

Download PDF Visit The Full Archive

Related Articles

Drug Company Cries Foul Over Clams Of Taxotere’s Superiority To Taxol

June 11, 1993

DCAB Board Okays One Contract Concept, Sends Another Back to Drawing Board

May 22, 1981

Counter-Point: George Sledge Responds To Berry’s Letter: Neoadjuvant Doesn’t Predict Adjuvant In Breast Cancer

July 11, 2014

FDA Advisors Recommend Use of Cytokines GM-CSF, G-CSF In BMT And Chemotherapy

January 4, 1991

Drug Shortages: Institutions Report Halting Enrollment in Clinical Trials

March 22, 2013

NCI To Stop All Support For WHT After March 31

February 5, 1988